CINGW CINGULATE INC C/WTS 03/12/2026 (TO PUR COM)
- 0.0150
- 0.00000.00%
CINGULATE INC C/WTS 03/12/2026 (TO PUR COM) News
Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
KANSAS CITY, Kan., April 16, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the twelve months ended December 31, 2023, and provided a clinical and business update.
Cingulate to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., March 19, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform techno
Cingulate to Attend DCAT Week 2024 in New York City
KANSAS CITY, Kan., March 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to Its Board of Directors
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Announces Closing of $7.5 Million Public Offering
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed Release
Cingulate Announces Pricing of $7.5 Million Public Offering
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest Into Cingulate Equity at Premium to Market
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform
Cingulate Receives Guidance From FDA on Path Forward for Anxiety Asset CTx-2103 (Buspirone)
KANSAS CITY, Kan., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate
Cingulate to Host CNS Key Opinion Leader Panel in New York City
Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR Drug Delivery Platform InnovationsKANSAS CITY, Kan., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a bi
Cingulate Inc. to Present at the LD Micro Main Event XVI
KANSAS CITY, Kan., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Cingulate Announces Closing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed
Cingulate Announces Pricing of $4.0 Million Public Offering
KANSAS CITY, Kan., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING) ("Cingulate," the "Company," "we," "our" or "us"), a biopharmaceutical company utilizing its proprietary Precision Timed
Cingulate Announces Detailed Trial Results From Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for ADHD
CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI-S) Scores, with Investigators Observing Trend Toward Significance
Werth Family Investment Associates Converts $5.8 Million of Debt Into Cingulate Equity at a Premium
Conversion Follows $1.0 Million Capital Investment in August 2023KANSAS CITY, Kan., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizin
Cingulate Announces Presentation of Full Trial Results From Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for ADHD at Psych Congress 2023
Data Accepted as Finalist for First Annual Poster AwardsKANSAS CITY, Kan., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Pre
Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update
Cingulate Announces Positive Top-Line Results From Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (Dexmethylphenidate) for ADHD
Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and DurationKANSAS CITY, Kan., July 11, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceu
Analysis
Price Target
No Data
